Nature Communications · 2019 · 99 citations · 42 references
MedicineMedicinal ChemistryPharmacologyMolecular PharmacologyPharmacodynamicsSignal TransductionLigand BindingMolecular DockingProtein-ligand DockingReceptor BindingReceptor ModelingReceptor-ligand InteractionsConformational Changes In ReceptorsFarnesoid X Receptor AgonistsFarnesoid X Receptor SignalingMolecular Property TuningTuning
The bile acid-sensing transcription factor farnesoid X receptor (FXR) regulates multiple metabolic processes. Modulation of FXR is desired to overcome several metabolic pathologies but pharmacological administration of full FXR agonists has been plagued by mechanism-based side effects. We have developed a modulator that partially activates FXR in vitro and in mice. Here we report the elucidation of the molecular mechanism that drives partial FXR activation by crystallography- and NMR-based structural biology. Natural and synthetic FXR agonists stabilize formation of an extended helix α11 and the α11-α12 loop upon binding. This strengthens a network of hydrogen bonds, repositions helix α12 and enables co-activator recruitment. Partial agonism in contrast is conferred by a kink in helix α11 that destabilizes the α11-α12 loop, a critical determinant for helix α12 orientation. Thereby, the synthetic partial agonist induces conformational states, capable of recruiting both co-repressors and co-activators leading to an equilibrium of co-activator and co-repressor binding.
42
Identification of a Nuclear Receptor for Bile Acids
Makoto Makishima, Arthur Y. Okamoto, Joyce J. Repa et al. · Science · 1999 · 2.7K citations
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Derek J. Parks, Steven G. Blanchard, Randy K. Bledsoe et al. · Science · 1999 · 2.2K citations
Brent A. Neuschwander‐Tetri, Rohit Loomba, Arun J. Sanyal et al. · The Lancet · 2014 · 2.2K citations